All patients in our AD-related MCI group underwent both Aβ and tau PET, and 82% were classified as tau stage C, so the substantial tau pathology in this group may explain why depressive symptoms showed a fully mediating effect specifically on executive function and attention. The gene discussed is MAPT; the disease is Alzheimer disease.